BioPharmSignal logoBioPharmSignal

Biotech News

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

Humacyte (HUMA)HumacyteCommercial

DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul

Related news

HUMAHumacyte2026-04-24 12:00 EST

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

HUMAHumacyte2026-10-15 12:00 EST

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

View all latest news

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

HUMAHumacyte2026-10-15 12:00 EST

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

HUMAHumacyte2026-10-12 12:00 EST

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

HUMAHumacyte2026-09-28 12:00 EST

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

HUMAHumacyte2026-09-10 12:00 EST

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

HUMAHumacyte2026-09-09 12:00 EST

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

Stock data

Close
0.41 USD
Market cap
308.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States